Tumor mutational burden is a determinant of immune-mediated survival in breast cancer

Mounting evidence supports a role for the immune system in breast cancer outcomes. The ability to distinguish highly immunogenic tumors susceptible to anti-tumor immunity from weakly immunogenic or inherently immune-resistant tumors would guide development of therapeutic strategies in breast cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Alexandra, Routh, Eric D., Pullikuth, Ashok, Jin, Guangxu, Su, Jing, Chou, Jeff W., Hoadley, Katherine A., Print, Cristin, Knowlton, Nick, Black, Michael A., Demaria, Sandra, Wang, Ena, Bedognetti, Davide, Jones, Wendell D., Mehta, Gaurav A., Gatza, Michael L., Perou, Charles M., Page, David B., Triozzi, Pierre, Miller, Lance D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207420/
https://www.ncbi.nlm.nih.gov/pubmed/30386679
http://dx.doi.org/10.1080/2162402X.2018.1490854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207420/
https://www.ncbi.nlm.nih.gov/pubmed/30386679
http://dx.doi.org/10.1080/2162402X.2018.1490854

Ejemplares similares